Chugai Pharmaceutical Co., Ltd.
Stock Price Chart
2026/03/05 UpdatedPrice Trend
2026/03/05 UpdatedPrice & Trading Details
2026/03/05 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
9.3M | +0.01% | |
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
8.3M | +0.27% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
5.9M | +2.67% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
5.6M | -4.54% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
4.6M | -0.66% | |
|
NEW PERSPECTIVE FUND
|
4.2M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
5.3K | -3.20% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥272 | +177.6% |
| 2024 | ¥98 | +22.5% |
| 2023 | ¥80 | +2.6% |
| 2022 | ¥78 | +2.6% |
| 2021 | ¥76 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥999,758M | ¥1,259,726M | ¥1,111,367M | ¥1,170,611M |
| Gross Profit | ¥661,612M | ¥783,475M | ¥698,061M | ¥831,201M |
| Operating Income | ¥421,897M | ¥533,308M | ¥439,174M | ¥542,002M |
| Pretax Income | ¥419,433M | ¥531,227M | ¥443,848M | ¥542,002M |
| Net Income | ¥302,995M | ¥374,429M | ¥325,472M | ¥387,317M |
| EPS | ¥184.17 | ¥227.57 | ¥197.80 | ¥235.36 |
| Operating Margin | 42.20% | 42.34% | 39.52% | 46.30% |
| Balance Sheet | ||||
| Total Assets | ¥1,538,694M | ¥1,869,758M | ¥1,932,547M | ¥2,208,373M |
| Total Equity | ¥1,188,017M | ¥1,424,387M | ¥1,625,580M | ¥1,901,499M |
| Total Liabilities | ¥350,677M | ¥445,371M | ¥306,967M | ¥306,874M |
| Cash | ¥267,753M | ¥222,169M | ¥458,674M | ¥540,202M |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 77.21% | 76.18% | 84.12% | 86.10% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥279,626M | ¥243,582M | ¥409,925M | ¥447,600M |
| Investing CF | -¥118,927M | -¥145,465M | -¥37,290M | -¥227,365M |
| Financing CF | -¥107,408M | -¥145,641M | -¥139,331M | -¥141,006M |
| Free CF | ¥206,760M | ¥172,343M | ¥335,667M | ¥392,701M |
| Efficiency | ||||
| ROE | 25.50% | 26.29% | 20.02% | 20.37% |
| ROA | 19.69% | 20.03% | 16.84% | 17.54% |
Latest IR Information
-
Fiscal Year Ending December 2025 Consolidated Financial Results [IFRS] Supplementary Materials
For the fiscal year ending December 2025, revenue was JPY 1,257.9 billion (YoY +7.5%), operating income was JPY 598.8 billion (YoY +10.5%), and net income was JPY 434.0 billion (YoY +12.1%), achieving growth in both revenue and profits.
Read more -
Notice Regarding Revision of Stock Compensation Plan
Chugai Pharmaceutical will abolish the restricted stock compensation plan and introduce a trust-based stock compensation plan. Implementation is planned upon approval at the shareholders meeting on March 26, 2026.
Read more -
Notice Regarding Dividend from Surplus
The fiscal year-end dividend for the term ending December 2025 is 147 yen per share (ordinary dividend 72 yen, 100th anniversary commemorative dividend 75 yen), raising the annual dividend to 272 yen. The total dividend amount is 241.92 billion yen,...
Read more -
Announcement of F. Hoffmann-La Roche Ltd.'s Fiscal 2025 Financial Results
F. Hoffmann-La Roche Ltd. announced its fiscal 2025 financial results. Chugai Pharmaceutical is a consolidated subsidiary of Roche Holdings, the parent company, holding 59.89% of issued shares as of the end of December 2025.
Read more -
(Progress of Disclosures) Notice Regarding Completion of Full Acquisition and Absorption-type Merger of Renalis Pharma Co., Ltd.
Chugai Pharmaceutical Co., Ltd. completed the full acquisition of Renalis Pharma Co., Ltd. on November 27, 2025, and finalized the absorption-type merger with Chugai Pharmaceutical Co., Ltd. as the surviving company and Renalis Pharma Co., Ltd. as the absorbed company...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥9,460
Rating Score: 2.13 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.
